MIG AG

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

PDC Biotech GmbH is a biotechnology company based in Vienna, Austria, specializing in the development of innovative therapeutics for the treatment of preterm labor and primary dysmenorrhea, both of which represent significant unmet medical needs. Established in 2008, PDC Biotech focuses on creating a pipeline of products that act as antagonists of the prostaglandin F2α (FP) receptor. Its key products include PDC31, a synthetic octapeptide designed as an allosteric modulator of the FP receptor, and the PDC41 Series, which offers a non-intravenous formulation for self-administration in primary dysmenorrhea. The company employs various delivery methods for its formulations, including nasal, sublingual, pulmonary, vaginal, and rectal suppositories. PDC Biotech has secured exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc., further enhancing its position in the biopharmaceutical landscape.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.